文献速递免疫规划卫生政策与健康促进

加强全球疫苗药物警戒:含麻疹-腮腺炎疫苗接种后无菌性脑膜炎与免疫性血小板减少性紫癜的概念验证研究

Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination.
PubMed 文献 · Vaccine · 2017-05-27

世界卫生组织在六个区域16个国家的26个哨点(49家医院)开展概念验证研究,采用自控风险区间法评估含麻疹-腮腺炎疫苗首剂接种后免疫性血小板减少性紫癜(ITP)和无菌性脑膜炎(AM)的风险。结果显示含麻疹疫苗首剂后ITP的发病率比为5.0(95%CI:2.5-9.7),含腮腺炎疫苗后AM的发病率比为10.9(95%CI:4.2-27.8),并发现特定疫苗株的风险升高。研究表明国际医院网络用于罕见疫苗不良事件评估是可行的。

要点

  • 含麻疹疫苗首剂后ITP风险升高,发病率比5.0(95%CI:2.5-9.7)
  • 含腮腺炎疫苗后AM风险升高,发病率比10.9(95%CI:4.2-27.8)
  • 含Schwarz、Edmonston-Zagreb和Enders'Edmonston株麻疹疫苗的ITP风险显著升高

核心结论

  • 该概念验证研究首次表明,使用共同标准化程序且中低收入国家高度参与的国际医院网络调查罕见疫苗不良事件是可行的,能产生可靠结果,并有可能描述疫苗株间的风险差异。

研究设计与样本

  • 概念验证研究,采用自控风险区间法作为主要分析,评估含麻疹-腮腺炎疫苗首剂接种后ITP和AM的风险。
  • 世界卫生组织选取分布于六个区域16个国家的26个哨点(49家医院)。

主要发现

  • 含麻疹疫苗首剂接种后ITP的发病率比为5.0(95%CI:2.5-9.7)。
  • 含腮腺炎疫苗后AM的发病率比为10.9(95%CI:4.2-27.8)。
  • 含Schwarz株麻疹疫苗的ITP发病率比为20.7(95%CI:2.7-157.6)。
  • 含Edmonston-Zagreb株麻疹疫苗的ITP发病率比为11.1(95%CI:1.4-90.3)。
  • 含Enders'Edmonston株麻疹疫苗的ITP发病率比为8.5(95%CI:1.9-38.1)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

New vaccines designed to prevent diseases endemic in low and middle-income countries (LMICs) are now being introduced without prior record of utilization in countries with robust pharmacovigilance systems. To address this deficit, our objective was to demonstrate feasibility of an international hospital-based network for the assessment of potential epidemiological associations between serious and rare adverse events and vaccines in any setting. This was done through a proof-of-concept evaluation of the risk of immune thrombocytopenic purpura (ITP) and aseptic meningitis (AM) following administration of the first dose of measles-mumps-containing vaccines using the self-controlled risk interval method in the primary analysis. The World Health Organization (WHO) selected 26 sentinel sites (49 hospitals) distributed in 16 countries of the six WHO regions. Incidence rate ratios (IRR) of 5.0 (95% CI: 2.5-9.7) for ITP following first dose of measles-containing vaccinations, and of 10.9 (95% CI: 4.2-27.8) for AM following mumps-containing vaccinations were found. The strain-specific analyses showed significantly elevated ITP risk for measles vaccines containing Schwarz (IRR: 20.7; 95% CI: 2.7-157.6), Edmonston-Zagreb (IRR: 11.1; 95% CI: 1.4-90.3), and Enders'Edmonston (IRR: 8.5; 95% CI: 1.9-38.1) strains. A significantly elevated AM risk for vaccines containing the Leningrad-Zagreb mumps strain (IRR: 10.8; 95% CI: 1.3-87.4) was also found. This proof-of-concept study has shown, for the first time, that an international hospital-based network for the investigation of rare vaccine adverse events, using common standardized procedures and with high participation of LMICs, is feasible, can produce reliable results, and has the potential to characterize differences in risk between vaccine strains. The completion of this network by adding large reference hospitals, particularly from tropical countries, and the systematic WHO-led implementation of this approach, should permit the rapid post-marketing evaluation of safety signals for serious and rare adverse events for new and existing vaccines in all settings, including LMICs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Perez-Vilar S, Weibel D, Sturkenboom M, et al. Enhancing global vaccine pharmacovigilance: Proof-of-concept study on aseptic meningitis and immune thrombocytopenic purpura following measles-mumps containing vaccination. Vaccine. 2017. PMID: 28558983. doi:10.1016/j.vaccine.2017.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。